Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial

CONCLUSIONS
In patients with type 2 diabetes and a recent ACS, the risk of CV death was higher after a postrandomization, nonfatal CV event, particularly heart failure, compared with those who did not experience a CV event. The risk of CV death was similar between alogliptin and placebo.

Source: Diabetes Care - June 20, 2016 Category: Endocrinology Authors: White, W. B.; Kupfer, S.; Zannad, F.; Mehta, C. R.; Wilson, C. A.; Lei, L.; Bakris, G. L.; Nissen, S. E.; Cushman, W. C.; Heller, S. R.; Bergenstal, R. M.; Fleck, P. R.; Cannon, C. P.; for the EXAMINE Investigators Tags: Cardiovascular and Metabolic Risk Source Type: research